Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersChromocell Therapeutics (AMEX:CHRO) stock increased by 21.6% to $1.49 during Friday's pre-market session. The company's market cap stands at $8.7 million. Kineta (NASDAQ:KA) stock moved upwards
Erasca's Promising Naporafenib Data and Financial Stability Merit a Buy Rating
Erasca Is Maintained at Buy by Goldman Sachs
Erasca Is Maintained at Buy by Goldman Sachs
Goldman Sachs Maintains Buy on Erasca, Raises Price Target to $7
Goldman Sachs analyst Chris Shibutani maintains Erasca with a Buy and raises the price target from $6 to $7.
Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript
Analysts Are Bullish on These Healthcare Stocks: Erasca (ERAS), Disc Medicine (IRON)
Earnings Call Summary | Erasca(ERAS.US) Q4 2023 Earnings Conference
The following is a summary of the Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript:Financial Performance:Erasca ended Q4 2023 with a cash balance of $322 million, excluding the
Erasca Inc (ERAS) Aligns With EPS Projections, Reveals Robust Balance Sheet and Key Clinical ...
Erasca's Strong Clinical Data and Enhanced Financial Position Support Buy Rating
Erasca Secures Funding for Future Growth Through Private Placement
Erasca Shares Climb After 4Q Loss Narrows, $45 Million Private Placement
By Dean Seal Shares of Erasca jumped after the company narrowed its loss in the fourth quarter and nabbed $45 million in an oversubscribed private placement. The stock was up 13% at $2.33 in premark
Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Erasca (ERAS)
HC Wainwright & Co. Reiterates Buy on Erasca, Maintains $8 Price Target
HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca with a Buy and maintains $8 price target.
Erasca to Get $45M Funding via Private Placement
Erasca Announces $45 Million Oversubscribed Private Placement Financing
SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS) ("Erasca"), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients
Erasca GAAP EPS of -$0.20
Erasca Q4 EPS $(0.20) Beats $(0.21) Estimate
Erasca Q4 EPS $(0.20) Beats $(0.21) Estimate
Erasca 4Q Loss/Shr 20c >ERAS
Erasca 4Q Loss/Shr 20c >ERAS
Press Release: Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib,
No Data